The US FDA has issued a complete response letter (CRL) on Green Cross Corp.'s biologics license application for I.V.-Globulin SN (IVIG-SN), a human immunoglobulin G for intravenous administration, which although set to delay an approval is not expected by analysts to exact a serious toll on the South Korean company's North American business plans.
The plasma-derived product is administered to protect the body against infection. Green Cross's BLA, filed in November 2015, was intended...







